{"result": {"id": "chatcmpl-124", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "**CABOZANTINIB** is a drug used to treat aggressive human pituitary tumors.  It inhibits multiple tyrosine kinase receptors, including vascular endothelial growth factor receptor (VEGFR), and is currently under investigation in the METEOR trial. \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743143179, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 50, "prompt_tokens": 196, "total_tokens": 246, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"CABOZANTINIB\"\nDescription List: [\"A drug used to treat aggressive human pituitary tumors\", \"Cabozantinib is a drug currently under investigation in the METEOR trial. It is also known to inhibit multiple tyrosine kinase receptors, including vascular endothelial growth factor receptor (VEGFR) enzymes. \\n\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_e1a943799f07a53bc2b9512caf2d90ff58224e47df2cf4c3324a1bee8197683f_v2"}